SCHEDULE: Greenhouse Funds Takes 5.8% Stake in NeoGenomics
Beneficial Ownership Report
Greenhouse Funds LLLP and its affiliates have disclosed a 5.8% passive ownership stake in cancer diagnostics firm NeoGenomics, Inc.
Summary
- Greenhouse Funds LLLP, Greenhouse GP LLC, and Joseph Milano collectively reported beneficial ownership of 7,431,147 shares of NeoGenomics, Inc. common stock.
- This aggregate amount represents 5.8% of NeoGenomics, Inc.'s outstanding common stock.
- The reporting persons hold shared voting power over 6,658,116 shares and shared dispositive power over all 7,431,147 shares.
- The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a significant passive investment by an institutional entity, which is generally viewed as a positive signal of confidence in the company's value and prospects.
Positives
- The acquisition of a 5.8% stake by Greenhouse Funds LLLP and its affiliates signals a significant institutional investment in NeoGenomics, Inc.
- The filing indicates a passive investment strategy, suggesting confidence in the company's current management and strategic direction without intent to influence control.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding NeoGenomics, Inc.'s future performance or strategic direction.
Industry Context
This filing indicates a notable institutional investment in NeoGenomics, Inc., a company operating in the specialized and growing field of cancer diagnostics. Such investments can reflect investor confidence in the long-term prospects of the healthcare technology and diagnostics sector, particularly in areas with high unmet medical needs like oncology.
Stakeholder Impact
- Shareholders may view the significant stake by Greenhouse Funds LLLP as a positive endorsement of NeoGenomics, potentially leading to increased investor confidence and interest in the stock.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (crossing the 5% ownership threshold). |
| 08/13/2025 | Date the Schedule 13G filing was signed and submitted. |
Keywords
NeoGenomics, Greenhouse Funds, Beneficial Ownership, Institutional Investment, Schedule 13G, Cancer Diagnostics, Healthcare, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.